Clinical Trials Logo
  1. Home
  2. Type 1 Diabetes
  3. NCT04810780
  4. Details
NCT04810780 Clinical Trial

Safety and Efficacy of DUO Extended Set: Combined Glucose Sensor and Infusion Set.

Type 1 Diabetes Clinical Trial

Official title:
Safety and Efficacy of DUO Extended Set: Combined Glucose Sensor and Infusion Set.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04810780
Other study ID # Sheba-20-7386-at-ctil
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date December 1, 2021

Study information
Verified date May 2022
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will follow subjects for 28 days while using an DUO extended infusion set combined with glucose sensor. the objective is to evaluate saftey and efficacy of the set in adult patient with type 1 diabetes.

Recruitment information / eligibility
Status Completed
Enrollment 10
Est. completion date December 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Clinical diagnosis of type 1 diabetes for at least one year 2. Using a MiniMed™ 670G or 640G Insulin pump with Guardian sensor 3. Age 18 to 80 years 4. Hemoglobin A1c level less than or equal to 10% 5. Not currently known to be pregnant, nor planning pregnancy during the study. 6. Willingness to follow the protocol and sign the informed consent Exclusion Criteria: 1. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. 2. Pregnant or lactating females 3. Subject has Glycosylated hemoglobin (HbA1c) > 10 % at time of screening.

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• DUO Extended Set
to evaluate saftey and efficacy of DUO extended set combined with glucose sensor

Locations
Country Name City State
Israel Sheba Medical Center Tel-Hashomer

Sponsors (2)
Lead Sponsor Collaborator
Sheba Medical Center Medtronic

Country where clinical trial is conducted

Israel, 

Outcome
Type Measure Description Time frame Safety issue
Primary Primery Effectivness Endpoint Precent of catheters reaching 7- day without set failure. 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4